<SEC-DOCUMENT>0001062993-17-001140.txt : 20170301
<SEC-HEADER>0001062993-17-001140.hdr.sgml : 20170301
<ACCEPTANCE-DATETIME>20170228174425
ACCESSION NUMBER:		0001062993-17-001140
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170227
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170301
DATE AS OF CHANGE:		20170228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17649690

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>February
27, 2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><div align="center"><B><U>Nevada </U></B></div></TD>
    <TD align=left width="33%"><div align="center"><B><U>000-52138 </U></B></div></TD>
    <TD align=left width="33%"><div align="center"><B><U>20-2000871 </U></B></div></TD></TR>
  <TR vAlign=top>
    <TD align=left><div align="center">(State or other jurisdiction of </div></TD>
    <TD align=left width="33%"><div align="center">(Commission File Number) </div></TD>
    <TD align=left width="33%"><div align="center">(IRS Employer </div></TD></TR>
  <TR vAlign=top>
    <TD align=left><div align="center">incorporation) </div></TD>
    <TD align=left width="33%"> <div align="center"></div></TD>
  <TD align=left width="33%"><div align="center">Identification No.) </div></TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><div align="center"><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></div></TD>
    <TD align=left width="50%"><div align="center"><B><U>V1X 3M4 </U></B></div></TD></TR>
  <TR vAlign=top>
    <TD align=left><div align="center">(Address of principal executive offices) </div></TD>
    <TD align=left width="50%"><div align="center">(Zip Code) </div></TD></TR>
  <TR>
    <TD align=left> <div align="center"></div></TD>
  <TD align=left width="50%"><div align="center"></div></TD></TR>
  <TR vAlign=top>
    <TD align=left><div align="center">Registrant&#146;s telephone number, including area code </div></TD>
    <TD align=left width="50%"><div align="center"><B><U>(250) 765-6424
    </U></B></div></TD></TR></TABLE>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp; Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp; ]&nbsp;
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))<BR></P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; Regulation FD
Disclosure </B></P>
<P align=justify>A copy of the news release announcing that has received a
Notice of Acceptance from the Australian Patent Office is filed as exhibit 99.1
to this current report and is hereby incorporated by reference. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Financial
Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated February
      27, 2017 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date:&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;February 28, 2017 </TD>
    <TD align=left width="50%">&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A><br>
<IMG
src="lexlogo.jpg"
border=0> <BR>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B><FONT size=5>Lexaria Receives Notice of its First Patent to
be Granted in Australia for Cannabinoid Infused Edibles </FONT></B></P>
<P align=justify>Kelowna, BC / February 27, 2017 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) is pleased to announce it
has received a Notice of Acceptance from the Australian Patent Office that
Lexaria&#146;s Australian patent application 2015274698 has been accepted with a
patent issuance date expected in June, 2017. This establishes Lexaria&#146;s first
successful acceptance for patent issuance outside of the USA, in what the
Company expects will be a series of successful international patent awards. </P>
<P align=justify>The Notice of Acceptance covers Lexaria patent application
entitled &#147;Food and beverage compositions infused with lipophilic active agents
and methods of use thereof&#148;, which has been accepted with the same set of claims
previously issued in US Patent No 9,474,725 specific to non-psychoactive
cannabinoids.</P>
<P align=justify>Lexaria is very pleased with the rapid advancement of its
patent claims by the Australian Patent Office and notes Australia&#146;s recent
federal legislative success in opening the medical cannabis market. Like Canada,
the medical cannabis market in Australia is federally legal. </P>
<P align=justify>&#147;Lexaria&#146;s technology is needed not just in the US, but
throughout the global cannabis sector, which is why we have patent applications
in place in 42 countries around the world,&#148; said Chris Bunka, CEO. &#147;Our
international applications offer the safety of unparalleled diversification to
our supporters that even individual national market leaders cannot offer.&#148; The
accepted patent application includes a series of Lexaria&#146;s method claims for
combining non-psychoactive cannabinoid lipophilic active agents together with a
bioavailability and taste enhancing oil by way of dehydration or lyophilization,
and doing so in contact with a food product substrate material. Lexaria still
has a number of additional patent applications undergoing review by the USPTO
and patent application continuations planned in order to further broaden its
expected set of compositional and method patent claims regarding the technology
for application with other molecules such as psychoactive cannabinoids;
vitamins; NSAIDs; and Nicotine.</P>
<P align=justify>The Company continues to thank its many supporters who have
contributed to its intellectual property success. </P>
<P align=justify>About Lexaria <BR>Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company&#146;s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
improving taste. This technology promotes healthy ingestion methods, lower
overall dosing and higher effectiveness in active molecule delivery. The
Company&#146;s technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify><U><FONT color=#0000ff>www.lexariabioscience.com
</FONT></U><BR>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Chris Bunka<BR>Chairman &amp; CEO<BR>(250) 765-6424 <BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. There is no
assurance that the expected Australian patent granting will occur in June 2017
or at any point in the future and there is no assurance that any additional
patents will be granted in the USA or in any other global location. Access to
capital, or lack thereof, is a major risk and there is no assurance that the
Company will be able to raise required working capital. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements. There is no assurance that any planned corporate activity, business
venture, or initiative will be pursued, or if pursued, will be successful. There
is no assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages
for the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria Energy Foods and ViPova<SUP>TM </SUP>products
are not intended to diagnose, treat, cure or prevent any disease.</P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lexlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lexlogo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !( (X# 2(  A$! Q$!_\0
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?6****!A1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
